NONMEM Users Network Archive

Hosted by Cognigen

[NMusers] Boston Intro to R for PK & Boston Enterprise Applications of the R Language (EARL)

From: Christina Halliday <>
Date: Mon, 2 Oct 2017 16:51:54 +0000

Hi Everyone,
Mango Solutions are running the following 2 day public training course in B=
oston later this month.

Course:Intro to R for Pharmacometrics
Date: Oct 30-31 2017
Location: BOSTON

The R for PK course is designed to review the basic concepts of the R langu=
age, before moving onto more Pharmacometric-based topics (such as producing=
 typical PK graphics, fitting mixed effects models, interacting with NONMEM=
 and performing simulation-based analyses).All our courses are very much ha=
nds-on, with theory backed up by relevant worked exercises & examples.
Each attendee also receives a Mango training certificate and 3 months post =
course support provided from Mango's technical helpdesk. Commercial and Aca=
demic rates are available for this course.

To find out more, for a full course outline or to register your interest pl=
ease email;<> w=
here a dedicated member of our Pharma team will be happy to assist.

Our Boston EARL (Enterprise Application of the R Language) conference is al=
so being held 1-3 November and we have some excellent speakers from the Pha=
rma sector again this year along with some great R learning workshops. To s=
ee the agenda and purchase tickets please visit<htt=

Kind regards



This message is intended for the use of the named recipient(s) only and may=
confidential and / or privileged information. If you are not the intended r=
ecipient, please
contact the sender and delete this message. Any unauthorised use of the inf=
contained in this message is prohibited.

Mango Business Solutions Limited is registered in England under No. 4560258=
 with its
registered office at Suite 3, Middlesex House, Rutherford Close, Stevenage,=
 Herts, SG1 2EF,


Received on Mon Oct 02 2017 - 12:51:54 EDT

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to: Once subscribed, you may contribute to the discussion by emailing: